Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.

被引：0

作者：

Eggermont, Alexander M.

Blank, Christian U.

Mandala, Mario

Long, Georgina V.

Atkinson, Victoria

Dalle, Stephane

Haydon, Andrew Mark

Meshcheryakov, Andrey

Khattak, Muhammad

Carlino, Matteo S.

Sandhu, Shahneen Kaur

Puig, Susana

Ascierto, Paolo Antonio

Christopher, Alexander

Van Akkooi, Jonathan

Krepler, Clemens

Ibrahim, Nageatte

Marreaud, Sandrine

Kicinski, Michal

Suciu, Stefan

Robert, Caroline

机构：

[1] Princess Maxima Ctr, Utrecht, Netherlands

[2] Netherlands Canc Inst, Amsterdam, Netherlands

[3] ASST Papa Giovanni XXIII, Bergamo, Italy

[4] Univ Sydney, Melanoma Inst Australia, Royal North Shore Hosp, Mater Hosp, Sydney, NSW, Australia

[5] Univ Queensland, Brisbane, Qld, Australia

[6] Hosp Civils Lyon, Pierre Benite, France

[7] Alfred Hosp, Melbourne, Vic, Australia

[8] NN Blokhin Canc Res Ctr, Moscow, Russia

[9] Univ Western Australia, Fiona Stanley Hosp, Perth, WA, Australia

[10] Westmead Hosp, Sydney, NSW, Australia

[11] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[12] Hosp Clin Barcelona, Barcelona, Spain

[13] Fdn IRCCS Ist Nazl Tumori, Naples, Italy

[14] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands

[15] Wistar Inst Anat & Biol, Philadelphia, PA USA

[16] Merck & Co Inc, Kenilworth, NJ USA

[17] EORTC Headquarters, Brussels, Belgium

[18] Gustave Roussy, Villejuif, France

[19] Paris Saclay Univ, Villejuif, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

10000

引用

页数：2

共 26 条

[21] Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.
Eggermont, Alexander M. M.
Chiarion-Sileni, Vanna
Grob, Jean Jacques
Dummer, Reinhard
Wolchok, Jedd D.
Schmidt, Henrik
Hamid, Omid
Robert, Caroline
Ascierto, Paolo Antonio
Richards, Jon M.
Lebbe, Celeste
Ferraresi, Virginia
Smylie, Michael
Weber, Jeffrey S.
Maio, Michele
Hosein, Fareeda
de Pril, Veerle
Kicinski, Michal
Suciu, Stefan
Testori, Alessandro
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[22] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial (vol 16, pg 522, 2015)
Eggermont, A. M. M.
Chiarion-Sileni, V
Grob, J-J
LANCET ONCOLOGY, 2015, 16 (06): : E262 - E262
[23] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. (vol 16, pg 522, 2015)
Eggermont, A. M. M.
Chiarion-Sileni, V
Grob, J-J
LANCET ONCOLOGY, 2016, 17 (06): : E223 - E223
[24] Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial
Eggermont, A. M. M.
Chiarion-Sileni, V.
Grob, J-J.
Dummer, R.
Wolchok, J. D.
Schmidt, H.
Hamid, O.
Robert, C.
Ascierto, P. A.
Richards, J. M.
Lebbe, C.
Ferraresi, V.
Smylie, M.
Weber, J. S.
Taitt, C.
de Pril, V.
de Schaetzen, G.
Suciu, S.
Testori, A.
ANNALS OF ONCOLOGY, 2016, 27
[25] Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
Coens, Corneel
Suciu, Stefan
Chiarion-Sileni, Vanna
Grob, Jean-Jacques
Dummer, Reinhard
Wolchok, Jedd D.
Schmidt, Henrik
Hamid, Omid
Robert, Caroline
Ascierto, Paolo A.
Richards, Jon M.
Lebbe, Celeste
Ferraresi, Virginia
Smylie, Michael
Weber, Jeffrey S.
Maio, Michele
Bottomley, Andrew
Kotapati, Srividya
de Pril, Veerle
Testori, Alessandro
Eggermont, Alexander M. M.
LANCET ONCOLOGY, 2017, 18 (03): : 393 - 403
[26] Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
Eggermont, Alexander M. M.
Chiarion-Sileni, Vanna
Grob, Jean-Jacques
Dummer, Reinhard
Wolchok, Jedd D.
Schmidt, Henrik
Hamid, Omid
Robert, Caroline
Ascierto, Paolo Antonio
Richards, Jon M.
Lebbe, Celeste
Ferraresi, Virginia
Smylie, Michael
Weber, Jeffrey S.
Maio, Michele
Hosein, Fareeda
de Pril, Veerle
Kicinski, Michal
Suciu, Stefan
Testori, Alessandro
EUROPEAN JOURNAL OF CANCER, 2019, 119 : 1 - 10

← 1 2 3 →